Single- and Multiple-Dose Randomized Studies of Blosozumab, a Monoclonal Antibody Against Sclerostin, in Healthy Postmenopausal Women

Abstract excerpt

Two clinical studies were conducted to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses (intravenous [iv] and subcutaneous [sc]) of blosozumab in postmenopausal women, including prior/current bisphosphonate (BP) users. In these phase 1, randomized, subject- and investigator-blind, placebo-controlled studies, subjects received escalating doses of...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Bone health and osteoporosis research
• Share to Rheumatoid Arthritis Research and Therapies
• Share to Systemic Sclerosis and Related Diseases